Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATIS-NVAF: Antithrombotic Therapy in Stroke with NVAF and Atherothrombosis
NCT03062319Phase 4Terminated
- Sponsor
- National Hospital Organization Osaka National Hospital
- Start
- Apr 2017
- Primary completion
- Jul 2023
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ischemic stroke, Atrial fibrillation (AFib) and atherothrombosis (2 arms), sponsored by National Hospital Organization Osaka National Hospital. Primary endpoint: Composite endpoint of ischemic cardiovascular events and major bleeding at 2 years. Started Apr 2017; status: terminated.
02
Conditions
ischemic strokeAtrial fibrillation (AFib)atherothrombosis
Beyond the preview
Go deeper on NCT03062319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062319.